Management of Acute Hepatitis A Infection
Acute hepatitis A is a self-limited disease requiring primarily supportive care, as no specific antiviral treatment has proven effective. 1, 2, 3
Initial Assessment and Diagnosis
Confirm the diagnosis serologically with IgM anti-HAV antibody testing in any patient presenting with acute viral hepatitis symptoms, as clinical presentation alone cannot distinguish hepatitis A from other viral hepatitides. 4, 5 Note that in rare cases, initial testing may be negative at symptom onset, warranting repeat testing if clinical suspicion remains high. 6
Key clinical features to assess:
- Symptom severity: fever, malaise, anorexia, nausea, abdominal discomfort, dark urine, jaundice 5
- Age-related presentation: children <6 years are typically asymptomatic (70%), while >70% of adults develop jaundice 5
- Risk factors: household/sexual contact, international travel, men who have sex with men, injection drug use 1
Supportive Management
Outpatient vs. Inpatient Care
Hospitalize patients who develop dehydration from nausea/vomiting, show signs of fulminant hepatitis, or have underlying chronic liver disease. 1, 2 Most uncomplicated cases can be managed in the community. 7
Specific Supportive Measures
- No dietary restrictions are necessary 1
- No activity restrictions are required 1
- Avoid hepatotoxic medications and alcohol completely during the acute illness 1, 2
- Use caution with any medications metabolized by the liver 1, 2
- Provide antiemetics and hydration for symptomatic relief as needed 7
Monitoring for Complications
Acute Liver Failure Surveillance
Monitor coagulation studies (prothrombin time/INR) and factor V levels closely to identify patients progressing toward fulminant hepatic failure, which occurs in 0.1-0.3% of cases overall but reaches 1.8% in adults >49 years. 1, 7
Critical warning signs requiring intensive monitoring:
- Development of encephalopathy (defines fulminant hepatic failure) 7
- Prolonged jaundice >7 days before encephalopathy onset (poor prognostic sign) 7
- Age >40 years (higher risk for fulminant course) 7
- Pre-existing chronic liver disease (increased risk of acute liver failure) 4, 5
If fulminant hepatic failure develops, immediately refer for liver transplant evaluation, as this represents the only definitive treatment for patients who progress to grade 4 encephalopathy despite medical management. 3, 7
Management of Atypical Presentations
Relapsing Hepatitis (10-15% of cases)
Continue supportive care through relapses, which can occur over 6 months but ultimately resolve without chronic sequelae. 4, 2, 8 No specific intervention alters the relapsing course. 9
Prolonged Cholestasis
Manage symptomatically with antipruritic agents if needed; this variant also resolves spontaneously without specific treatment. 9
Extrahepatic Manifestations
Recognize rare complications including maculopapular rash, polyarthralgia, autoimmune hemolytic anemia, acute kidney injury, and neurologic manifestations. 6, 9 These require supportive management and typically resolve with the underlying hepatitis.
Contact Tracing and Prevention
Immediately identify and provide post-exposure prophylaxis to close contacts (household members, sexual partners, persons with ongoing close personal contact). 4
Administer immune globulin (IG) 0.02 mL/kg IM to unvaccinated contacts within 2 weeks of exposure, which is >85% effective in preventing infection. 1, 4, 2, 4 Do not delay IG administration for anti-HAV antibody testing. 4
Vaccinate contacts who receive IG and for whom hepatitis A vaccine is recommended (men who have sex with men, injection drug users, persons with chronic liver disease). 1, 4, 2
Expected Clinical Course
Reassure patients that symptoms typically last <2 months with complete recovery expected. 2, 5 Peak infectivity occurs in the 2 weeks before jaundice onset, with viral shedding declining after jaundice appears. 5
HAV infection does not cause chronic liver disease or chronic infection, and recovery confers lifelong immunity. 1, 2, 8
Key Clinical Pitfalls
- Do not assume negative initial IgM anti-HAV excludes the diagnosis—repeat testing if clinical suspicion persists 6
- Do not overlook underlying chronic liver disease, which significantly increases risk of acute liver failure 4, 5
- Do not delay contact tracing and post-exposure prophylaxis, as efficacy of IG declines rapidly after 2 weeks 1, 4
- Do not prescribe corticosteroids or other immunosuppressive therapy—these have no proven benefit in acute hepatitis A 3